





Shots to Save Lives
AN ISSUE BRIEF FROM TRUST FOR AMERICA’S HEALTH,
THE INFECTIOUS DISEASES SOCIETY OF AMERICA, AND
THE ROBERT WOOD JOHNSON FOUNDATION
The 2009 novel H1N1 flu outbreak has been a serious reminder that thereis no strong mechanism in place for vaccinating adults in the United
States.  Public health departments are struggling with how to reach adults in
communities around the country to encourage them to get vaccinated against
H1N1, the seasonal flu, and, in some cases, pneumonia in a short period of
time, without any real infrastructure in place.
It is unfortunate, but not surprising, that be-
tween 40,000 and 50,000 adults die annually
from vaccine preventable diseases in the
United States.  Millions of American adults go
without routine and recommended vaccina-
tions because our medical system is not set up
to ensure adults receive regular preventive
health care.  The result is thousands of deaths
from seasonal influenza, invasive pneumococ-
cal disease, the effects of hepatitis B, and other
infectious diseases that could have been pre-
vented each year if more adults were vacci-
nated.1 The U.S. Centers for Disease Control
and Prevention (CDC) has estimated the direct
health care burden of adult vaccine-pre-
ventable diseases at about $10 billion annually.2
CDC recommends that adults should be vac-
cinated against a range of diseases, including
chickenpox, diphtheria, hepatitis A and B,
human papillomavirus, influenza, measles,
meningococcal disease (meningitis), mumps,
pertussis (whooping cough), pneumococcal
disease (pneumonia), rubella, shingles, and
tetanus.3 Recommendations for some spe-
cific vaccines vary depending on an individ-
ual’s risk factors and age.
Despite the recommendation of medical ex-
perts about the effectiveness and safety of
these adult vaccines, immunization rates re-
main low.  Currently, there is no real system
or structure in place to ensure adults have
access to or receive the vaccines they need
unless they are part of institutions that have
vaccine requirements, such as being en-
rolled in colleges or universities, serving in
the military, or working in health care set-
tings.  Significant numbers of adults do not
have regular well care exams and switch
doctors and health plans often, which
makes it extremely difficult to set up ways
for people to know what vaccines they need
and for doctors to track and recommend
vaccines to patients.
In addition, lack of health insurance cover-
age and high costs can be an obstacle.  Private
medical insurance does not always pay for
adult vaccinations, and many patients can not
afford vaccines, some of which are expensive.
Even governmental program support is in-
consistent.  Medicaid coverage varies among
states, and the Medicare process for vaccine
payment is often bureaucratic and cumber-
some, and not all recommended adult vac-
cines are covered under Medicare Part B,
resulting in out-of-pocket costs that can be
prohibitive for some older Americans.  
According to the National Immunization Survey
released by CDC in 2007:4
 Only 2.1 percent of eligible adults (18 to 64
years old) had the tetanus, diphtheria, and
whooping cough vaccine in the previous
two years;
 Just under two percent of older patients (60
and over) had the shingles vaccine;
 Only 10 percent of eligible adult women (18
to 26 year olds) had the human papillo-
mavirus (HPV) vaccine;
 Only 36.1 percent of all adults are vaccinated
annually for the seasonal flu.  Seniors, ages 65
and older, are considered most at risk for
complications from the flu, and the CDC rec-
ommends all seniors receive a flu shot and the
pneumonia vaccine.  Yet only 69 percent of
seniors, ages 65 and older, had the flu vaccine
in 2008.  Only 58 percent of Medicare bene-
ficiaries received flu vaccines; and
 Only 66.9 percent had the pneumococcal vac-
cine, which is far short of the CDC’s goal of a
90 percent vaccination rate for seniors.5
The consequences are severe in terms of deaths
and illnesses that could have been prevented.
For instance, each year, approximately 36,000
Americans die of the seasonal flu, 5,000 die from
pneumonia, and more than one million adults
get shingles, an extremely painful condition that
causes a blistering skin rash.6, 7 In addition, ap-
proximately 20 million Americans ages 15 to 49
are currently infected with HPV and are at risk
for cervical cancer, and more than 800,000 to
1.4 million Americans are estimated to have
chronic viral hepatitis B infection.8, 9  
According to the National Center for
Immunization and Respiratory Diseases,
vaccine-preventable diseases kill more
Americans every year than traffic accidents,
breast cancer, or HIV/AIDS.10
Leading scientific and medical organizations, in-
cluding CDC and the Infectious Diseases Soci-
ety of America (IDSA), have called for the
development of a strong adult immunization
program to help prevent these unnecessary
deaths and illnesses.  Concerns about the need
for an adult vaccine strategy have intensified
with the novel H1N1 experience, and awareness
of the importance of vaccines as a response to
many biological terrorism threats, such as small-
pox or anthrax continues to grow.
This paper reviews reasons why adult vaccination
rates are so low and outlines a series of recom-
mendations for actions needed to develop and
implement an effective strategy to make sure
American adults have the opportunity to receive
the vaccines recommended by medical experts.
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VACCINE SUCCESSES
There is considerable evidence that immunizations are effective:  
 In the United States, mass vaccination has eliminated polio; 
 Smallpox has been eradicated worldwide through widespread immunization;
 Among U.S. children, the recommended immunization series prevents approximately 10.5 million
cases of infectious illness a year and 33,000 deaths;11  
 An economic evaluation of the impact of seven vaccines -- diphtheria, tetanus, and pertussis (DPT),
tetanus and diphtheria (Td), Haemophilus influenzae type b (Hib), polio, hepatitis B, and varicella
(chicken pox), and measles, mumps, and rubella (MMR),  routinely given to children found that
these seven vaccines prevent more than 14 million cases of disease and more than 33,500 deaths
during the lifetime of children born in any given year in the United States, and annually save $10 bil-
lion in direct medical costs and more than $40 billion in indirect societal costs.12 With widespread
childhood hepatitis B vaccinations, experts predict there will be a dramatic decline in liver cancer
cases among the next generation of adults; and
 A report issued by the World Health Organization (WHO), UNICEF and the World Bank found that
three million lives are saved worldwide each year through childhood immunizations, a number that
could even be higher with more funding.13 
3ROUTINE PREVENTABLE DISEASES WITH ADULT VACCINES AVAILABLE TO
PREVENT THEM14
Adults need vaccinations for new diseases and “booster” shots for diseases that they were vaccinated
against as children, because their immunity may wane over time.  In addition, new vaccines are being
developed against old diseases, and adults can benefit from these vaccines as they become available.
Vaccinations against diseases, such as pneumococcal and influenza, are especially important for people
at high risk, including those suffering from chronic illnesses such as heart disease, pulmonary disease,
diabetes, alcoholism or chronic liver disease (cirrhosis), and for health care professionals and care-
givers.  Also, Americans who travel to certain foreign countries may need vaccines to protect against
diseases that exist in those regions but are not prevalent in the United States.
Vaccines go through rigorous review and testing for effectiveness and safety by the U.S. Food and
Drug Administration (FDA) before they are released to the market.  The safety of vaccines is tracked
through a monitoring system to keep track of potential patterns of adverse side effects.
The Vaccine Adverse Event Reporting System (VAERS) is a joint CDC and FDA program that works
with manufacturers, health care providers, and members of the public to report possible adverse events
that people experience following vaccinations.15 In addition, the Vaccine Safety Datalink (VSD) project is
a collaboration between CDC’s Immunization Safety Office (ISO) and eight large managed-care organi-
zations to monitor safety and answer scientific questions about vaccine side effects.16  
 Diphtheria: Diphtheria is a serious bacterial disease that frequently causes heart and nerve prob-
lems. Without treatment, 40 to 50 percent of infected persons die, with the highest death rates oc-
curring in the very young and the elderly.  Diphtheria has largely been eradicated in the United
States and other industrialized nations through widespread vaccination.  There were only five re-
ported cases of diphtheria between 2000 and 2007 in the United States.17 
 Hepatitis A:  Each year in the United States, hepatitis A infection sickens 125,000 to 200,000 peo-
ple, resulting in 70 to 100 deaths. Hepatitis A disease tends to occur in outbreaks sometimes attrib-
uted to many people having eaten from the same infected food source or transmission from person
to person in family settings. 
 Hepatitis B:  National studies show that about 12.5 million Americans have been infected with hep-
atitis B virus at some point in their lifetimes. More than 10 percent of infected individuals develop
chronic infection, increasing chances for chronic liver disease, cirrhosis and liver cancer. Hepatitis B-
related liver disease kills about 5,000 people and costs $700 million annually in health care and pro-
ductivity-related costs.
 Human Papillomavirus (HPV):  Approximately 20 million Americans currently are infected with
HPV, and another 6.2 million people become newly infected each year. At least 50 percent of sexu-
ally active men and women acquire genital HPV infection at some point in their lives. HPV can lead
to cervical cancer. The HPV vaccine includes protection against the two HPV strains that cause 70
percent of all cervical cancers.
 Influenza:  Many illnesses are called “flu.”  These include respiratory as well as gastrointestinal disorders
and can be caused by a variety of infectious agents.  Influenza is a specific respiratory infection caused by
influenza viruses.  Influenza vaccine protects against influenza, not the other disorders. In an average
year, influenza causes approximately 36,000 deaths and 200,000 hospitalizations in the United States.
THERE’S A LEGITIMATE CONCERN IN THE PUBLIC ABOUT VACCINE SAFETY BECAUSE
VACCINES ARE GIVEN TO HEALTHY PEOPLE. FOR THAT REASON, THERE IS A VERY HIGH LEVEL
OF RESPONSIBILITY TO ENSURE THAT THEY ARE SAFE AND DO NOT CAUSE HARM. 
- EDWARD A. BELONGIA, MD, MARSHFIELD CLINIC RESEARCH FOUNDATION
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4 Pertussis:  Also known as whooping cough, pertussis is
highly contagious and can result in prolonged coughing
spells that may last for many weeks or even months. Ap-
proximately 50 out of every 10,000 people who develop
pertussis die from the disease. Since the 1980s, the number
of reported pertussis cases has steadily increased, especially
among adolescents and adults.18 In 2004, a total of 25,827
cases of pertussis were reported to the CDC, the highest
number since 1959.  Of these, 7,008, or 27 percent, oc-
curred among those between age 19 and 64.  Young infants
who die from pertussis often catch the infection from an
adult or adolescent.
 Pneumococcal disease:  The pneumococcal bacterium is
spread by coughing and sneezing. It is the most common cause
of pneumonia, inflammation of the coverings of the brain and
spinal cord (meningitis), bloodstream infection (sepsis), ear in-
fections and sinus infections (sinusitis) in children under two
years of age.  The elderly are especially susceptible to this in-
fection. In 2006, there were approximately 41,000 cases of in-
vasive pneumococcal disease, resulting in 5,000 U.S. deaths.  
 Tetanus:  Commonly known as lockjaw, tetanus is a severe
disease that causes stiffness and spasms of the muscles, with
approximately 30 percent of reported cases ending in death.
Tetanus bacteria grow in soil and are an ongoing threat.  In
the United States, mortality due to tetanus has declined at a
constant rate due to the widespread use of tetanus toxoid–
containing vaccines since the late 1940s.  According to CDC,
in 2005, a total of 27 tetanus cases and 2 deaths were re-
ported to the national tetanus surveillance system.19
 Zoster (Shingles)20:  Zoster (shingles) is a very painful nerve
infection caused by the same virus as chickenpox and is often
accompanied by a localized skin rash with blisters.  Anyone who
has had chickenpox can develop shingles because the virus re-
mains in the nerve cells of the body after the chickenpox infec-
tion clears and can emerge years later to cause shingles.  The
disease most commonly occurs in people 50 years and older,
and those with compromised immune systems.  There are ap-
proximately one million zoster cases annually; one in three
Americans will get shingles in their lifetime; frequently shingles
and post-herpetic neuralgia increase with age.
ADDITIONAL CHILDHOOD VACCINE-PREVENTABLE DISEASES
In addition to the adult immunizations, there are also a
number of other immunizations that are recommended
during childhood, including:
 Haemophilus influenzae type b (Hib):  Prior to the vac-
cine, Hib meningitis killed 600 children each year, and
caused seizures among many survivors as well as perma-
nent deafness, and mental retardation. Since the vaccine’s
introduction in 1987, the incidence of serious Hib bacteria
infection has declined by 98 percent in the United States.
 Measles:  As a result of widespread vaccination, measles
is no longer endemic in the United States.  However, be-
cause measles is still widespread in many countries, the
United States is at risk of “importation” of the disease,
and if high immunity is not maintained in adults and chil-
dren, there is a risk of re-establishment of endemic trans-
mission.  Measles is highly contagious.  In the first half of
2008, CDC received reports of 131 measles cases from
15 states and the District of Columbia -- the highest year-
to-date number since 1996.21 More than 90 percent of
those infected had not been vaccinated or their vaccina-
tion status was unknown.  In the United States, roughly
one in five people who develop measles require hospital-
ization for one or more complications from the disease.  
 Meningococcal disease:  Meningococcal disease is a se-
rious bacterial illness, and is a leading cause of bacterial
meningitis in children two through 18 years old in the
United States. About 1,000 - 2,600 people get meningo-
coccal disease each year in the United States and 10-15
percent of these people die. Young college students living
in dormitories and military recruits living in barracks are
especially vulnerable.
 Mumps:  Prior to the mumps vaccine, the United States
suffered approximately 200,000 cases of mumps per
year with 20 to 30 deaths. Since a second dose of
mumps vaccine was added to the standard childhood
immunization series, annual cases are now in the
hundreds rather than the thousands. 
 Rotavirus:  Rotavirus is a disease of the digestive tract
caused by any one of three strains of rotavirus. Infection
causes acute gastroenteritis (vomiting and diarrhea), and
humans of all ages are susceptible to rotavirus infection.
According to CDC, each year rotavirus is responsible for
more than 400,000 doctor visits; more than 200,000
emergency room visits; 55,000 to 70,000 hospitalizations;
and between 20 and 60 deaths in the United States. 
 Rubella:  Before the rubella vaccine was introduced, wide-
spread outbreaks mostly affected children in the 5-9 year
age group. Between 1962 and 1965, rubella infections dur-
ing pregnancy were estimated to have caused 30,000 still
births and 20,000 children to be born impaired or disabled. 
 Varicella/Chickenpox:  Although generally mild, vari-
cella (chickenpox) is a highly contagious virus that can
lead to severe illness with complications such as second-
ary bacterial infections, severe dehydration, pneumonia,
central nervous system deficits/disease and shingles.
Chickenpox has been reduced by 80 percent in the
United States since the introduction of the vaccine.22
5INFLUENZA: Health care personnel need an influenza vaccination every year. Unvaccinated health
care workers can spread influenza to patients and are a key cause of influenza outbreaks among pa-
tients and long-term care residents. The vaccine does not cause influenza.
HEPATITIS B: Five to 10 percent of acute hepatitis B infections lead to chronic infection, and these
lead to liver damage (cirrhosis), liver cancer, or death. Hepatitis B vaccine should be given to protect
individuals who are in contact with blood, body fluids, or used needles.
MEASLES/MUMPS/RUBELLA (MMR): Health care workers who are not already immune to MMR
should be vaccinated. Even mild or undetectable rubella disease can cause birth defects. 
TETANUS/DIPHTHERIA/PERTUSSIS (Td/Tdap): Health workers need a booster every 10 years
for Td (tetanus-diphtheria) vaccine, and Tdap should replace a single dose of Td for adults who have
not received a dose of Tdap previously.  Persons may receive Tdap if it has been at least two years
since the last Td vaccination.  Health workers who are injured and/or who have direct patient contact
should be especially vigilant about booster shots.
VARICELLA (CHICKENPOX): Varicella can be transmitted in hospitals by patients, staff, and visi-
tors. Health workers who are not already immune should be vaccinated.
CDC’S IMMUNIZATION RECOMMENDATIONS TO HEALTH CARE WORKERS24
FUTURE POSSIBLE VACCINATIONS
A number of additional vaccinations are in the research and development phase.  Scientists hope that
many additional vaccines are on the horizon for both infectious and chronic diseases.  Most of the cur-
rent vaccinations in wide use are focused on infectious diseases, but there are a number of potentially
promising vaccines aimed at chronic disease issues and factors that contribute to chronic disease or be-
havior health, including smoking, drug use, and obesity.  A smoking vaccine is currently in clinical trials.23
Recommended: U.S. authorities recommend certain vaccines to protect travelers from illnesses present
in other parts of the world and to prevent the importation of infectious diseases across international bor-
ders. The vaccinations travelers need depend on several factors, including destination, whether the indi-
vidual will be spending time in rural areas, the season of the year, age, health status, and previous
immunizations. The CDC recommends travelers visit its destinations page at http://wwwn.cdc.gov/travel/
destinations/list.aspx to learn which vaccines they may need for specific countries.
Required: The only immunization required by international health regulations is yellow fever vaccination for
travel to certain countries in sub-Saharan Africa and tropical South America. Saudi Arabia requires meningo-
coccal vaccination during the Hajj (the annual Muslim pilgrimage to Mecca) and documentation of polio vac-
cination must be presented for children 15 years of age and younger.
VACCINES FOR TRAVELERS25
I. PNEUMOCOCCAL AND SEASONAL
INFLUENZA VACCINATIONS
To illustrate the low rates of adult vaccinations,
TFAH conducted an analysis of the number of
seniors who have been vaccinated against pneu-
monia and adults who have been vaccinated
against the seasonal flu in each state.  These rep-
resent the two most successful campaigns for
adult immunizations, yet the number of adults
who get vaccinated is still relatively low.
Pneumonia Vaccinations for Seniors
CDC has recommended that all seniors, ages 65
and older, should be vaccinated against pneumo-
nia, and HHS has set a national goal of immuniz-
ing 90 percent of seniors by the year 2010.  This
shot is only required once in a lifetime for most
people.  As of 2008, only 66.9 percent of seniors
have received the vaccine.28 Vaccination rates
range from a low of 55.4 percent in the District of
Columbia and a high of 73.2 percent in Oregon.
CDC also recommends that anyone over the age
of two with underlying health problems (such as
asthma, heart disease, lung disease, sickle cell dis-
ease, diabetes, alcoholism, cirrhosis, and other
chronic diseases), with a disease that lowers the
body’s resistance to infection (such as Hodgkin’s
disease, or HIV/AIDS), who smoke, or who are
taking any drug or treatment that lowers the
body’s resistance to infection (such as long-term
steroids or radiation therapy), should get immu-
nized against pneumonia. 
People with flu, particularly seniors, are at risk for
developing pneumonia as a complication.  Pneu-
monia can be lethal, particularly in older adults.
Together with flu, pneumonia is the eighth lead-
ing cause of death in the United States.  
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VACCINES DURING PREGNANCY
Pregnant women have a higher risk of complications from influenza compared with the general popu-
lation.  Women who may become pregnant should consult with their health care providers to ensure
they are current on routinely recommended vaccines.  It is recommended that women who become
pregnant should receive the inactivated seasonal flu shot and women should receive the Tdap vaccine
before they become pregnant.26 In addition, the MMR vaccine can prevent birth defects due to infec-
tion with rubella during pregnancy.  Anyone receiving either the MMR or varicella (chickenpox) vac-
cine should wait four weeks before becoming pregnant.  If a woman is already pregnant, she should
wait until after delivery to get either of these vaccines.
The H1N1 outbreak demonstrated the need for pregnant women to receive flu vaccinations, as they
suffered higher rates of severe reactions than the general population.27 
CHICKENPOX CAN MAKE YOU VERY SICK IF YOU ARE AN ADULT. ADULTS ARE 25 
TIMES MORE LIKELY TO HAVE A SEVERE CASE OF CHICKENPOX THAN CHILDREN. THE DISEASE
CAN RESULT IN DEATH. IN PREGNANT WOMEN, IT CAN CAUSE BIRTH DEFECTS. 
--ANNE GERSHON, MD, COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS, DEPARTMENT OF PEDIATRICS.
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7Pneumococcal Vaccination Rates for Adults Aged 65+
Percent Vaccinated Percent NOT Rank: 1= Lowest 
Vaccinated Vaccination Rate
Alabama 64.0% (+/- 1.8) 36.0% 8
Alaska 64.0% (+/- 4.4) 36.0% 8
Arizona 68.2% (+/- 2.3) 31.8% 30
Arkansas 64.2% (+/- 1.5) 35.8% 12
California 61.0% (+/- 1.9) 39.0% 3
Colorado 72.6% (+/- 1.3) 27.4% 50
Connecticut 66.6% (+/- 1.4) 33.4% 22
Delaware 70.0% (+/- 2.1) 30.0% 38
D.C. 54.4% (+/- 2.3) 45.6% 1
Florida 62.4% (+/- 1.3) 37.6% 4
Georgia 64.0% (+/- 1.6) 36.0% 8
Hawaii 67.9% (+/- 1.8) 32.1% 27
Idaho 64.7% (+/- 1.8) 35.3% 14
Illinois 59.6% (+/- 1.7) 40.4% 2
Indiana 66.9% (+/- 1.7) 33.1% 24
Iowa 70.1% (+/- 1.5) 29.9% 40
Kansas 68.5% (+/- 1.2) 31.5% 32
Kentucky 65.2% (+/- 1.6) 34.8% 16
Louisiana 66.3% (+/- 1.7) 33.7% 21
Maine 70.5% (+/- 1.7) 29.5% 43
Maryland 66.1% (+/- 1.6) 33.9% 19
Massachusetts 69.6% (+/- 1.1) 30.4% 36
Michigan 65.8% (+/- 1.4) 34.2% 18
Minnesota 70.8% (+/- 1.7) 29.2% 45
Mississippi 66.8% (+/- 1.4) 33.2% 23
Missouri 67.3% (+/- 1.9) 32.7% 26
Montana 71.2% (+/- 1.5) 28.8% 47
Nebraska 70.2% (+/- 1.3) 29.8% 41
Nevada 66.1% (+/- 2.4) 33.9% 19
New Hampshire 71.2% (+/- 1.5) 28.8% 47
New Jersey 63.5% (+/- 1.4) 36.5% 6
New Mexico 64.6% (+/- 1.6) 35.4% 13
New York 63.3% (+/- 1.6) 36.7% 5
North Carolina 68.8% (+/- 1.0) 31.2% 33
North Dakota 69.4% (+/- 1.7) 30.6% 35
Ohio 68.4% (+/- 1.7) 31.6% 31
Oklahoma 71.1% (+/- 1.3) 28.9% 46
Oregon 73.2% (+/- 1.5) 26.8% 51
Pennsylvania 69.7% (+/- 1.4) 30.3% 37
Rhode Island 71.8% (+/- 1.6) 28.2% 49
South Carolina 64.0% (+/- 1.4) 36.0% 8
South Dakota 64.7% (+/- 1.4) 35.3% 14
Tennessee 65.4% (+/- 1.9) 34.6% 17
Texas 63.7% (+/- 1.6) 36.3% 7
Utah 68.0% (+/- 1.9) 32.0% 28
Vermont 69.0% (+/- 1.4) 31.0% 34
Virginia 68.1% (+/- 2.0) 31.9% 29
Washington 70.0% (+/- 0.8) 30.0% 38
West Virginia 66.9% (+/- 1.8) 33.1% 24
Wisconsin 70.5% (+/- 1.8) 29.5% 43
Wyoming 70.3% (+/- 1.5) 29.7% 42
U.S. Total 66.9% 33.1% N/A
Source: Behavioral Risk Factor Surveillance System.  
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State 18-49 Year Olds 50-64 Year Olds 65 Years and Over Total
Alabama 26.3% (+/- 2.8) 41.8% (+/- 2.8) 68.7% (+/- 2.7) 37.9% (+/- 1.9)
Alaska 26.7% (+/- 3.5) 43.0% (+/- 4.9) 68.5% (+/- 6.3) 35.2% (+/- 2.8)
Arizona 22.2% (+/- 3.6) 39.4% (+/- 4.6) 71.4% (+/- 3.2) 34.8% (+/- 2.6)
Arkansas 27.7% (+/- 2.7) 44.9% (+/- 2.8) 70.5% (+/- 2.5) 40.1% (+/- 1.8)
California 18.4% (+/- 1.5) 39.5% (+/- 2.2) 70.0% (+/- 2.2) 30.8% (+/- 1.1)
Colorado 28.9% (+/- 1.6) 48.6% (+/- 1.9) 77.9% (+/- 1.7) 40.4% (+/- 1.2)
Connecticut 28.3% (+/- 2.6) 45.7% (+/- 3.0) 74.6% (+/- 2.4) 41.1% (+/- 1.8)
Delaware 26.1% (+/- 3.0) 46.7% (+/- 3.9) 69.6% (+/- 3.5) 38.8% (+/- 2.2)
D.C. 30.3% (+/- 2.8) 44.2% (+/- 3.3) 61.3% (+/- 3.5) 38.2% (+/- 2.0)
Florida 17.7% (+/- 2.5) 32.4% (+/- 2.8) 63.5% (+/- 2.5) 31.4% (+/- 1.7)
Georgia 21.8% (+/- 2.3) 38.6% (+/- 2.8) 65.2% (+/- 2.9) 31.8% (+/- 1.7)
Hawaii 31.9% (+/- 2.5) 47.4% (+/- 2.8) 77.1% (+/- 2.5) 44.2% (+/- 1.7)
Idaho 20.8% (+/- 2.3) 39.5% (+/- 2.8) 68.4% (+/- 2.9) 33.0% (+/- 1.7)
Illinois 20.8% (+/- 2.2) 38.6% (+/- 3.0) 63.2% (+/- 2.9) 31.9% (+/- 1.7)
Indiana 21.5% (+/- 2.6) 39.9% (+/- 3.1) 68.6% (+/- 3.1) 34.1% (+/- 1.9)
Iowa 32.7% (+/- 2.4) 48.2% (+/- 2.7) 76.5% (+/- 2.2) 44.8% (+/- 1.7)
Kansas 26.9% (+/- 2.0) 43.5% (+/- 2.1) 72.0% (+/- 1.9) 38.9% (+/- 1.4)
Kentucky 25.8% (+/-2.5) 43.6% (+/- 2.6) 73.6% (+/- 2.3) 38.6% (+/- 1.7)
Louisiana 27.5% (+/- 2.3) 43.6% (+/- 2.6) 68.0% (+/- 2.8) 38.2% (+/- 1.6)
Maine 25.0% (+/- 2.1) 47.3% (+/- 2.3) 74.6% (+/- 2.2) 40.6% (+/- 1.5)
Maryland 26.8% (+/- 2.0) 46.3% (+/- 2.4) 69.8% (+/- 2.5) 38.5% (+/- 1.4)
Massachusetts 28.5% (+/- 1.6) 45.8% (+/- 1.8) 72.0% (+/- 1.7) 40.5% (+/- 1.1)
Michigan 23.0% (+/- 1.8) 41.8% (+/- 2.1) 70.0% (+/- 2.0) 35.7% (+/- 1.3)
Minnesota 36.8% (+/- 2.9) 50.4% (+/- 2.9) 76.4% (+/- 2.6) 46.6% (+/- 2.0)
Mississippi 24.7% (+/- 2.2) 38.4% (+/- 2.3) 67.5% (+/- 2.2) 35.5% (+/- 1.5)
Missouri 26.5% (+/- 2.8) 45.1% (+/- 3.3) 71.3% (+/- 2.8) 39.2% (+/- 2.0)
Montana 25.3% (+/- 2.6) 40.9% (+/- 2.5) 69.3% (+/- 2.4) 37.8% (+/- 1.7)
Nebraska 33.0% (+/- 2.4) 51.3% (+/- 2.3) 75.7% (+/- 1.8) 45.2% (+/- 1.6)
Nevada 15.4% (+/- 2.3) 29.6% (+/- 3.5) 57.1% (+/- 3.9) 25.5% (+/- 1.8)
New Hampshire 28.9% (+/- 2.2) 49.4% (+/- 2.5) 78.1% (+/- 2.1) 42.6% (+/- 1.6)
New Jersey 22.9% (+/- 1.9) 39.9% (+/- 2.2) 65.9% (+/- 2.2) 34.8% (+/- 1.3)
New Mexico 28.0% (+/- 2.6) 42.3% (+/- 2.8) 69.7% (+/- 2.6) 38.6% (+/- 1.8)
New York 24.8% (+/- 2.1) 43.9% (+/- 2.6) 70.9% (+/- 2.4) 37.6% (+/- 1.5)
North Carolina 28.4% (+/- 1.7) 47.3% (+/- 1.9) 73.0% (+/- 1.6) 40.4% (+/- 1.2)
North Dakota 30.0% (+/- 2.8) 45.4% (+/- 2.7) 73.2% (+/- 2.4) 42.1% (+/- 1.9)
Ohio 24.2% (+/- 1.9) 42.0% (+/- 2.0) 70.3% (+/- 1.8) 37.1% (+/- 1.3)
Oklahoma 27.8% (+/- 2.0) 51.3% (+/- 2.4) 73.2% (+/- 2.1) 41.8% (+/- 1.4)
Oregon 20.7% (+/- 2.3) 43.2% (+/- 2.7) 70.1% (+/- 2.6) 35.3% (+/- 1.7)
Pennsylvania 23.7% (+/- 2.0) 43.2% (+/- 2.3) 71.7% (+/- 2.0) 38.3% (+/- 1.4)
Rhode Island 28.1% (+/- 2.8) 49.9% (+/- 3.0) 74.0% (+/- 2.6) 42.0% (+/- 2.0)
South Carolina 23.6% (+/- 2.3) 42.9% (+/- 2.7) 68.0% (+/- 2.4) 36.3% (+/- 1.6)
South Dakota 37.8% (+/- 2.7) 53.6% (+/- 2.6) 76.3% (+/- 2.1) 49.2% (+/- 1.8)
Tennessee 29.0% (+/- 3.2) 42.7% (+/- 3.1) 70.8% (+/- 2.8) 39.5% (+/- 2.1)
Texas 24.8% (+/- 1.9) 42.1% (+/- 2.5) 71.1% (+/- 2.2) 35.4% (+/- 1.5)
Utah 30.7% (+/- 2.4) 48.6% (+/- 3.2) 73.3% (+/- 3.0) 39.8% (+/- 1.8)
Vermont 26.1% (+/- 2.1) 46.9% (+/- 2.2) 73.4% (+/- 2.2) 40.2% (+/- 1.5)
Virginia 29.3% (+/- 3.3) 48.0% (+/- 3.6) 73.1% (+/- 3.1) 40.7% (+/- 2.4)
Washington 26.3% (+/- 1.3) 44.2% (+/- 1.4) 71.4% (+/- 1.4) 38.0% (+/- 0.9)
West Virginia 23.5% (+/- 2.4) 46.5% (+/- 2.9) 71.1% (+/- 2.8) 39.1% (+/- 1.8)
Wisconsin 28.9% (+/- 2.8) 44.4% (+/- 3.2) 73.0% (+/- 3.0) 40.5% (+/- 2.0)
Wyoming 27.7% (+/- 2.0) 44.8% (+/- 2.1) 70.7% (+/- 2.1) 39.5% (+/- 1.4)
National Totals 24.1% (+/- 0.5 ) 42.0% (+/- 0.5 ) 69.5% (+/- 0.5 ) 36.1% (+/- 0.7)
Source: Behavioral Risk Factor Surveillance System.  More information on the methodology for this analysis is available in Appendix D.
Seasonal Flu Vaccinations for Adults
The annual vaccine for seasonal flu is the largest
existing program for adult vaccinations in the
United States.  However, only a fraction of adults
receive this vaccine.  In some states, the rates of
adult vaccinations for the flu is as low as 25.5 per-
cent (Nevada), and even in the state with the high-
est vaccination rate, South Dakota at 49.2 percent,
less than half of the state’s population has been
vaccinated.  Seasonal flu vaccines have been largely
recommended for individuals above the age of 50,
since they are most at risk for health complications
related to the flu.  Even with targeted efforts to vac-
cinate individuals above the age of 65, the rates of
annual flu vaccinations for seniors is as low as 61.3
percent in D.C and no state exceeds 80 percent.
The highest rate is 77.9 percent in Colorado.
II. BARRIERS TO ADULT IMMUNIZATION
Several barriers keep the numbers of adult vac-
cinations low.  
 LIMITED ACCESS:  Most adults are outside
of institutionalized settings, like the military,
where vaccinations can be required;
 LIMITED CARE AND INSURANCE 
COVERAGE:  Primary and preventive care
for adults is limited, particularly for the
uninsured or underinsured;
 LIMITED FINANCING FOR
IMMUNIZATIONS:  Many adults have
medical insurance that does not pay for
vaccines and their administration, so out-of-
pocket costs may be prohibitive;
MISUNDERSTANDING AND MISINFOR-
MATION:  Many adults are misinformed
about the safety and effectiveness of vaccines;
and
 LIMITED REARCH AND DEVELOPMENT:
Vaccine research, development, and produc-
tion have been limited in the United States
for decades.
A.  LIMITED ACCESS:  FEW REQUIREMENTS FOR ADULT
VACCINATIONS EXIST
The United States has developed successful
childhood vaccination campaigns.  To protect
children from vaccine-preventable diseases,
states have enacted laws that require immuniza-
tion for the entry of children into the school sys-
tem and into child care facilities.  In addition, a
Vaccines for Children (VFC) program was cre-
ated to pay for vaccines for all children.  Ac-
cording to data from the 2006-2007 school year,
approximately three-quarters of the states al-
ready have reached the national Healthy People
2010 target of at least 95 percent coverage for
all vaccines recommended for children in
kindergarten.29 The high nationwide coverage
underscores the value of school-entry require-
ments in boosting vaccination coverage.
Creating a program to reach all adults is more
complicated.  For adults, there are no institu-
tions, such as schools, which could facilitate a
broad immunization requirement, although cer-
tain establishments like universities or the mili-
tary require some immunizations for adults who
are affiliated with these institutions.  For exam-
ple, many colleges require new students to prove
they have been immunized against MMR,
meningococcal disease and hepatitis B.  Military
personnel must also have certain vaccinations,
and, depending on deployment, receive addi-
tional immunizations to protect against such
bio-terror threats as smallpox and anthrax.
Nursing homes that receive Medicare payments
are required to offer seasonal influenza and
pneumococcal vaccinations to their residents,
but residents are not required to accept them.
Also, the requirement to offer the shots in nurs-
ing homes does not extend to the facility’s
health workers, staff, or visitors.  Some hospitals
and other health care facilities require an im-
munization review for specific vaccinations upon
admission of a patient or for new employees. 
B.  LIMITED CARE AND INSURANCE COVERAGE:  ADULT CARE
DOES NOT STRESS PRIMARY CARE OR PREVENTION
The American health care system for adults is
geared more toward treating illness than ensur-
ing wellness.  Many adults rarely see a primary
care physician or only go to a doctor when they
are sick or are managing chronic conditions.
And, many adults receive most of their medical
care from sub-specialists who do not consider im-
munizations their responsibility.  In addition,
many doctors are unaware of specific immuniza-
tion guidelines for adults, and many adult patients
are unaware that they need vaccinations.  And, a
significant number of adults -- an estimated 44 mil-
lion Americans -- lack access to primary health
care altogether.30  
Since vaccinations have not traditionally been
provided regularly as part of adult care, basic
systems are not well established for doctors to
provide them.  
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One problem for doctors is the difficulty in stor-
ing adult vaccines in their offices. Different vac-
cines have different temperature storage
requirements such as refrigeration or use of a
freezer, and even a short power loss can ruin an
entire inventory. Many small physician practices
do not have the facilities for backup power. Also,
the administration fee provided by some payors
does not include the cost of purchasing refriger-
ators/freezers and other storage costs.  And, even
if a doctor’s office stores vaccine, it is hard to pre-
dict how much vaccine they will need or use,
since most adult vaccines are recommended over
a period of 50 to 70 years, as compared to vac-
cines for children, which are mostly administered
during the first six years of life.  There is no guar-
antee that the adults in any one practice will gen-
erate enough demand for a particular vaccine, so
vaccines may have to be discarded once their “use
by” date expires, resulting in unreimbursed costs.
In addition, many health care workers themselves
do not get regularly recommended vaccinations.
A 2003 immunization survey conducted by CDC,
for example, showed seasonal influenza vaccina-
tion coverage of only 40 percent among health
care workers.31 Experts say that immunizations
are especially important for health care workers,
since they can transmit infections to their ill and
immune-compromised patients and vice versa.
This is considered an especially important issue
in hospitals and nursing homes, where many pa-
tients are elderly and at increased risk for in-
fluenza and pneumococcal disease. Vaccination
of health care personnel can reduce staff ill-
nesses, absenteeism, and the likelihood of sick-
ness and death among patients. 
Studies have consistently shown several additional
reasons why health care workers do not get in-
fluenza vaccinations.  The most frequent reason
unvaccinated workers gave for not getting the flu
shot was that they thought that they did not need
it.32 Some expressed concern about vaccine side
effects, including the erroneous belief that vac-
cine can cause the flu.  Others perceived them-
selves to be at low risk for catching the virus or
felt that getting vaccinated was an inconvenience. 
In addition, despite the scientific evidence to the
contrary, some doctors and medical providers
have unsubstantiated personal concerns about
vaccinations that cause them to dissuade patients
from receiving vaccines or they pass along mis-
information to their patients about vaccinations.
For instance, there were reports that a number
of health providers counseled their patients not
to get the novel Influenza H1N1 vaccine in spite
of the scientific evidence of the safety and effec-
tiveness of the vaccine.  Many public health ex-
perts recommend that increased education
about vaccinations should be included as part of
nursing, medical, and other health professional
educational curricula.  
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I GET A CARD FROM MY VETERINARIAN WHEN IT’S TIME TO BRING MY DOG AND CAT
IN FOR THEIR SHOTS. WHY DON’T I GET A CARD FROM MY DOCTOR WHEN IT’S TIME FOR ME
TO GET MINE? 
--GREGORY A. POLAND, MD, DIRECTOR, MAYO CLINIC VACCINE GROUP.
“
”
MANY DOCTORS ARE NOT VACCINE-SAVVY WITH RESPECT TO ADULTS, AND WE NEED
TO EDUCATE THEM. PRACTICES SHOULD HAVE ‘STANDING ORDERS,’ SO THAT EVERY PATIENT
WHO COMES IN IS SCREENED AND ASKED QUESTIONS ABOUT IMMUNIZATION -- AND THEN
RECEIVES THE VACCINES IF THEY ARE NEEDED.
--WILLIAM SCHAFFNER, MD, VANDERBILT UNIVERSITY SCHOOL OF MEDICINE, 
DEPARTMENT OF PREVENTIVE MEDICINE
“
”
In an effort to increase the number of adults
being vaccinated, a number of medical groups,
including the American College of Physicians
and the IDSA, are trying to increase awareness
within medical school curricula and among cer-
tain specialties, such as gynecology, which have
regularized patient contact.  So, for instance,
when women go for mammograms or Pap tests,
they could also have access to vaccinations.
In addition, flu vaccination campaigns are mak-
ing vaccines regularly available to individuals in
alternative sites outside of the medical care set-
ting, such as through drug stores and super-
markets.  During the novel Influenza H1N1
vaccination campaigns, a number of non-tradi-
tional sites were also used with success, includ-
ing airports, zoos, social service agencies, and
baseball parks.  Alternative sites could also be ex-
plored for other vaccinations beyond influenza.
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HEALTH CARE WORKERS OFTEN [MISTAKENLY] THINK THEY’RE IMMUNE. THEY’VE BEEN
WORKING IN THIS SETTING FOR A LONG TIME, HAVE BEEN AROUND SICK PEOPLE, AND
[WRONGLY] THINK THEY HAVE NATURAL DEFENSES.
-- PASCALE WORTLEY, MD, MPH, CHIEF, HEALTH SERVICES RESEARCH AND EVALUATION BRANCH, NATIONAL
CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES, CDC.
“
”
KEEPING TRACK OF VACCINATIONS
Effective tracking of adult immunization is important to help people avoid getting redundant or un-
necessary vaccinations.  Registries can maintain patient confidentiality while serving as good health
records for individuals and as a means to track population vaccination trends.33 Forty-nine states
have some form of childhood vaccination registry in effect.  Approximately 20 percent of adults
over 19 years of age have at least some immunization information in an immunization registry.  The
wider use of electronic medical records in the years ahead could make tracking vaccinations easier
for individuals and providers.
C.  LIMITED FINANCING FOR VACCINES:  LACK OF
INSURANCE COVERAGE LIMITS VACCINATIONS
One major obstacle to adult vaccinations is cost.  
A number of insurance programs, including 
some state Medicaid programs, do not cover the ac-
tual costs for doctors to administer vaccines.  Many
private insurers require patient co-payments for
vaccinations.34 Government programs cover ap-
proximately nine percent of adults younger than
65 years of age.  While federal funds from Section
317 of the Public Health Service Act given to states
can be used to help support adult vaccinations in
public health clinic settings, most of these funds are
used to support childhood immunization pro-
grams.35 The Section 317 program is a discre-
tionary federal grant program to all states, 6 cities,
territories and protectorates, which provides vac-
cines to underinsured children and adolescents
not served by the VFC program, and as funding
permits to uninsured and underinsured adults.36
In addition, Medicare coverage for vaccinations
for adults ages 65 and older is fragmented.
Medicare Part B pays for influenza, pneumo-
coccal, and hepatitis B vaccines, and covers
other vaccines only when they are related to an
injury -- tetanus, for example, or other direct ex-
posure to a disease.37 As of 2006, Medicare Part
D pays for all current and future vaccines not
covered by Part B; however recipients confront
obstacles in obtaining vaccines through
Medicare Part D, since the system is designed to
reimburse pharmacies rather than physicians.
Finally, the costs of several of the new adult vac-
cines are relatively expensive and can be a disin-
centive to vaccinating adults.  Zostavax®, the
approved vaccine against shingles, is one of the
most expensive vaccines on the market, as is Gar-
dasil®, an HPV vaccine.  (The cost of Zostavax®
can be as high as $200 or more for a single shot;
Gardasil®, costs up to $175 or more per dose and
three doses are needed per individual.)   
D.  MISUNDERSTANDING AND MISINFORMATION:  MISPERCEPTIONS
AND MYTHS KEEP SOME ADULTS FROM GETTING VACCINATED
Scientific research has shown that vaccines are
very safe.  While minor side-effects from vaccines
may develop, serious adverse events are ex-
tremely rare, and some are so rare that risk can-
not be accurately assessed.  Most vaccine adverse
events are minor and temporary, such as a sore
arm or mild fever, and can often be controlled
by taking a pain reliever before or after vaccina-
tion.  There are so few vaccine-related deaths
that it is impossible to assess the risk statistically.38
The benefits of vaccines greatly outweigh the po-
tential adverse effects.  Diseases such as measles,
mumps, and rubella have essentially been eradi-
cated from the United States and Europe in the
past 40 years due to widespread vaccination ef-
forts.39 Many adults in the United States or Europe
have never even known anyone with a case of
measles, mumps, or rubella, yet these diseases con-
tinue to plague other parts of the world where vac-
cination campaigns and consistently available
resources do not exist.  Due to unsubstantiated
fear over vaccinations and a complacent attitude
towards diseases adults have not encountered in
modern times, some adults have chosen not to vac-
cinate their children and/or themselves, and in
turn rates of certain vaccine-preventable diseases
have increased in recent years, highlighting the im-
portance of continued efforts to vaccinate.40    
With the current outbreak of 2009 novel H1N1 in-
fluenza, many questions regarding the safety of vac-
cines, specifically the H1N1 vaccines, have been
brought to the forefront of discussions.  Two
months after the first doses of the H1N1 vaccine
became available to the public an extensive review
of adverse effects indicated that the vaccine is safe.41
No side effects beyond those typical of the seasonal
flu vaccine were reported, and a very small num-
ber of serious adverse events have been reported. 
The importance of vaccinations cannot be over-
stated.  According to the CDC:
Perhaps the greatest success story in public health is the
reduction of infectious disease resulting from the use
of vaccines.  Routine immunization has eradicated
smallpox from the globe and led to the near elimina-
tion of wild polio virus.  Vaccines have reduced some
preventable infectious diseases to an all-time low, and
now few people experience the devastating effects of
measles, pertussis, and other illnesses.42  
When used in conjunction with education and
other public health measures, vaccinations can
continue to increase the quality and length of
life across the world.
Despite the evidence of safety and effectiveness
of vaccines, many adults are unaware that they
need certain vaccinations or are misinformed
about vaccines.  
According to the findings of a 2007 public opin-
ion survey by the National Foundation on Infec-
tious Diseases, many adults did not know that
adult vaccinations were available that could pro-
tect them from diseases for which they could be
at risk.43 Forty percent of respondents reported
that they did not think they needed vaccines be-
cause they were vaccinated as a child, 34 percent
were not concerned about catching diseases that
can be prevented by vaccines, 32 percent were
not concerned about spreading an illness to
friends, family, and co-workers, 25 percent
thought diseases prevented by vaccines are not se-
rious or life-threatening, and 18 percent said they
thought vaccines were not necessary for adults.
Despite the scientific evidence, a number of re-
spondents expressed concern about vaccine safety
or efficacy.  Thirty-five percent had heard or read
that vaccines are not safe, 25 percent reported
that they thought a vaccine made them sick, and
14 percent felt that vaccines do not work.
About one-fourth of respondents expressed con-
cern about cost.  Twenty-seven percent thought
insurance would not cover vaccines, 26 percent
thought vaccines are too expensive, and 22 per-
cent said they would not get vaccinated if they
had to pay for it.
Adult vaccination rates are particularly low for mi-
nority groups.  Researchers have found that
African Americans were significantly less likely
than whites to have positive attitudes toward in-
fluenza vaccination.44 According to 2008 data, 69
percent of older non-Hispanic whites received
the seasonal influenza vaccination, compared to
only 53 percent and 51 percent of older African
Americans and Hispanics, respectively.45 The gap
for pneumococcal vaccination coverage was even
greater; vaccination rates were 61 percent for
non-Hispanic whites, compared to 45 percent for
African Americans and 29 percent for Hispanics.
Researchers are trying to better understand the
reasons behind these disparities. Numerous stud-
ies have shown that economics, education, and
discrimination all are factors.46 This study sug-
gested that negative attitudes about vaccinations
among African Americans had much more influ-
ence over vaccination decisions than recommen-
dations from health care providers.
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Even some members of the medical community
express personal concern about vaccinations, de-
spite the scientific evidence of safety and efficacy,
which sometimes causes them to pass along mis-
information to patients or even refuse to vacci-
nate patients.  Public health experts recommend
greater efforts be made to help provide in-
creased education about the safety of vaccines to
medical providers who may have concerns, par-
ticularly to encourage providers to provide the
most up-to-date information to their patients.
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E.  RESEARCH AND DEVELOPMENT:  RAMPING UP
DISCOVERIES AND ADVANCES
Vaccine research and development can be ex-
pensive for pharmaceutical companies, and it is
often difficult for manufacturers to obtain the
development support needed to push a new vac-
cine toward profitability.  Studies have shown
that each new product reaching the market can
take up to a decade of development, and a fi-
nancial investment of up to $1 billion.47 In ad-
dition, the fact that the market for adult vaccines
can be limited, since vaccination rates are so low,
has discouraged many U.S. manufacturers from
major investment in vaccine development.
In recent years, Congress has enacted legislation
that makes it easier and faster for the HHS to
fund the development and procurement of new
medical countermeasures against bioterrorism
and some naturally-occurring emerging infec-
tious threats. Through the Biomedical Advanced
Research and Development Authority (BARDA),
the government has created measures to guar-
antee that they will pay manufacturers for vac-
cines and drugs produced for the Strategic
National Stockpile (SNS), once development is
complete.48 Unfortunately, since its creation,
BARDA has not been adequately funded to allow
the program to achieve its mission.  In fiscal year
(FY) 2010, BARDA received $305 million from
Congress.  Organizations such as the Center for
Biosecurity recommended BARDA receive $1.7
billion in FY 2010 to successfully carry out its mis-
sion and responsibilities.49 Furthermore, Con-
gress has authorized the HHS Secretary to
permit emergency use of critical products
through a streamlined, but temporary FDA li-
censure procedure.50 This emergency authority
eases some of the regulatory burden of getting a
new vaccine into the market.  In December 2009,
HHS Secretary Kathleen Sebelius announced
she was ordering a major review of policies for
developing medical countermeasures against
public health threats.51
FDA’s Center for Biologics Evaluation and Re-
search (CBER) is responsible for regulating and
licensing vaccines in the United States. Typi-
cally, the development of a new vaccine follows
an approval process similar to the one used for
drugs. Human studies are conducted in three
phases, the first, a small trial to look at safety
and to see if there is an immune response; the
second, to assess dosage; and the third and
largest to document efficacy. 
Today, many experimental vaccines are in pub-
lic and private sector vaccine development
pipelines, aimed at routine use in healthy pedi-
atric and adult populations, travelers, the mili-
tary, and potential emerging biological threats.52
Recent years have seen the introduction of several
important new vaccines, including those against
zoster (shingles) and HPV, as well as improved
versions of existing vaccines, such as the meningo-
coccal conjugate vaccine and a pertussis vaccine
that is effective in adolescents and adults (in-
cluded in Tdap vaccine). Work is underway on
vaccines for cytomegalovirus (CMV), a common
virus that can be passed by a pregnant woman to
her fetus, resulting in severe hearing, mental or
movement impairments; and group B Strepto-
coccus, a bacterium that can cause life-threaten-
ing infections in newborns and illness among
pregnant women, the elderly and those ill with
other conditions. 
Scientists are always working on new vaccines, as
well as trying to improve upon existing vaccines.
Efforts to develop a single vaccine that would
protect against all influenza viruses are under-
way, as is an extensive global program to design
and test candidate vaccines against HIV, which
causes AIDS, and for which there currently is no
vaccine available.  Also of global importance are
new vaccines that could protect against Ebola
and Marburg viruses, which cause hemorrhagic
fever; against malaria, a parasitic illness trans-
mitted by mosquitoes that causes one million
deaths every year, mostly in infants, young chil-
dren and pregnant women, and most of them in
Africa; and against tuberculosis (TB), which kills
approximately 2 million people worldwide an-
nually.   Scientists are also tackling non-infec-
tious conditions and are trying to develop new
vaccines that could prevent various types of can-
cer as well as brain diseases that might result in
substance abuse, such as cocaine, nicotine, and
methamphetamine addictions.
III.  COORDINATION BETWEEN THE FEDERAL
GOVERNMENT AND STATE AND LOCAL
HEALTH DEPARTMENTS 
While the federal government sets the guidelines
and many policies related to vaccinations, it is
the state and local health departments that man-
age both routine vaccination efforts on a regular
basis and emergency vaccinations in the event of
a new disease outbreak or bioterrorism event.  In
addition, each state has vaccination laws and re-
quirements, which the federal government sup-
ports by setting policies and providing funding.53
The federal Advisory Committee on Immuniza-
tion Practices (ACIP) determines which vaccines
to recommend and approves the vaccines, and
then state and local health departments organ-
ize, administer, and maintain vaccine campaigns
and registries.54 Most health departments around
the country hold their own vaccination clinics
and educate the public about the importance of
keeping up to date on immunizations.55
On a routine basis, public health departments
often administer childhood and adult vaccina-
tions in public-private partnerships with health
care providers.  For instance, health depart-
ments maintain clinics where children can come
for the vaccines they need for school as an al-
ternative to receiving the vaccinations from their
private pediatricians.  In addition, health de-
partments administer adult vaccinations
through clinics and often maintain flu vaccina-
tion clinics.  Being able to receive vaccinations
through health departments is particularly im-
portant to have for individuals and families who
are uninsured or underinsured.  
For example, in an effort to improve preteen vac-
cination rates, California implemented Preteen
Vaccine Week in 2009.56 Through kits and plan-
ning materials, educational materials, public serv-
ice announcements, and adolescent health
conferences, California raised awareness about
the ACIP recommendations for preteens.  Health
departments are using many avenues such as
schools, community centers, and local media to
improve vaccination rates in their communities.   
Another function of many state and local health
departments is to collect vaccination data and
maintain immunization registries.  These reg-
istries are often used to help ensure children and
adolescents keep up-to-date with immunizations.  
In 1998, in an effort to facilitate community- and
state-based immunization registry development,
the federal National Vaccine Advisory Committee
(NVAC) launched the Initiative on Immunization
Registries to facilitate local and state based im-
munization registries in the United States.  One
of the national health objectives for 2010 is to in-
crease to 95 percent the proportion of children
under 6 years of age who are part of a fully oper-
ational Immunization Information System (IIS).57
IIS are confidential, computerized information
systems that can record vaccination data about all
children within a certain geographic area.58 State-
and locally-based immunization registries are crit-
ical to effective documentation of vaccination cov-
erage; they enable implementation of vaccination
strategies, and they decrease resources needed to
measure, achieve, and maintain increased levels
of vaccination coverage.59
As health information technology advances in the
United States, many experts believe the inclusion
of registry-like information in electronic health
records may facilitate public health department
access to this information and make monitoring
immunizations by providers easier as well.
State and local health departments also play an
important role in immunizing Americans dur-
ing new outbreaks and crises, such as bioterror-
ism events.  The federal government maintains
the SNS, which includes countermeasures and
vaccines for emergencies, but state and local
health departments are responsible for the man-
agement and administration of vaccinations in
their jurisdictions.  State and local health de-
partments plan and train to: 1) receive SNS as-
sets from the federal government; 2) distribute,
or move, those assets from the storage facility to
the point-of-dispensing (POD); and 3) dispense,
provide, or administer the medical counter-
measure to the affected persons.  According to
the CDC, “preparedness to receive, stage, store,
and distribute SNS material is essential to saving
lives at risk during a public health emergency.”60
During the novel Influenza H1N1 outbreak, the
federal government purchased the vaccine and
distributed it to designated vaccination sites in
states through public-private partnerships, so
some vaccine went to the health departments,
some went to private health care providers, and
some went to other health care entities, such as
pharmacies, as determined by the state or terri-
torial health department.  Each state is respon-
sible for conducting its own vaccination
campaign.  For instance, in Virginia, the state
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IV.  CONCLUSION AND RECOMMENDATIONS
1. INCREASE DEMAND FOR ADULT VACCINES
Each year, hundreds of thousands of American
adults are hospitalized and tens of thousands
die from diseases that could have been pre-
vented by vaccination.  CDC estimates that the
cost of the health burden to society from vac-
cine preventable diseases is approximately $10
billion annually.  Initiating improvements in
the nation’s ability to immunize adults will pre-
vent disease, mitigate suffering, and reduce
health care costs. 
TFAH and IDSA recommend a number of actions
be taken to increase adult immunization rates for
vaccine-preventable illnesses. Many are based on
IDSA’s 2007 statement, Actions to Strengthen Adult
and Adolescent Immunization Coverage in the
United States: Policy Principles of the Infectious Dis-
ease Society of America.63 These recommendations
reflect the views of TFAH and IDSA and do not nec-
essarily reflect the views of those consulted on this
paper or those who served as peer reviewers. 
 If adult immunization coverage is to in-
crease, public and provider awareness must
be improved. 
With respect to public awareness, CDC
should receive additional resources to cre-
ate and manage a broad public education
campaign targeted at improving adult im-
munization rates, with active participation
by and collaboration with state and local
public health departments. Federal officials,
in partnership with medical societies and
public health departments, also must con-
duct an assertive campaign to combat the
rise in “vaccine hesitancy.”  Targeted infor-
mation that is culturally-appropriate should
be made available to high-risk groups and
racial and ethnic minority populations.
State and territories should receive ade-
quate resources to tailor immunization cam-
paigns and approaches to their own unique
and diverse populations at local levels.
 Professional medical societies (e.g., obstet-
rics/gynecology and internal medicine)
should support ongoing education of their
members about the importance of adult im-
munization.  Medical and nursing schools
should expand curricula on vaccine-pre-
ventable diseases in adults.
With respect to providers, it should become a
standard practice to review patients’ immuniza-
tion histories and offer vaccinations at appropri-
ate medical encounters. Providers should
consider routine preventive heath care visits,
such as cancer screenings and pre-natal visits, as
an opportunity to discuss the patient’s immu-
nization needs.  Providers and other parties
should work to establish purchasing cooperatives
to lower costs and risks to individual providers.
Hospitals and medical practices should promote
the use of standing orders for vaccinations.
 Providers should take advantage of advances in
electronic medical records or immunization
registries to improve information-sharing
about patients’ vaccination histories across dif-
ferent providers and to generate reminders to
providers and patients about recommended
vaccinations.  Federal standards for meaningful
use of health information technology (IT),
which will accompany health IT grants to
providers as part of the American Recovery
and Reinvestment Act (ARRA), should also in-
clude vaccine notification and tracking.
and local government and health departments
are using advertisements on buses and in movie
theaters, television and radio ads, temporary tat-
toos, t-shirts and stickers as part of their media
campaign to encourage residents to get vacci-
nated.61 Other states are using local health de-
partments to directly administer vaccinations.
In Jackson County, Ohio, the local health de-
partment set up vaccination sites throughout
the county including a weekday and weekend
clinic at the health department as well as school-
based clinics.62
WE’VE HAD SIGNIFICANT IMPROVEMENT IN GETTING CHILDREN IMMUNIZED...BUT IT’S
AN EMBARRASSMENT THAT WE HAVE DONE SO POORLY WITH ADULTS.
--CONGRESSMAN HENRY A. WAXMAN, CHAIRMAN OF THE HOUSE ENERGY AND COMMERCE COMMITTEE
“ ”
2. EXPAND EXISTING FEDERAL IMMUNIZATION PROGRAMS AND
CREATE A “VACCINES FOR UNINSURED ADULTS PROGRAM”
 Congress should increase funding for the Sec-
tion 317 Program.  In March 2009, CDC pro-
vided Congress with a professional judgment
estimate that the Section 317 Program would
require $1.6 billion in FY 2010 to fully protect
children who rely on this program and to ex-
tend the program to increase adult immu-
nization rates as well.  FY 2010 funding for the
program is only $496.8 million.  Congress al-
located an additional $300 million to the pro-
gram as part of the ARRA, with those funds to
be expended in FY 2009 and 2010, so that
funding should be built into the FY 2011 base-
line.  In addition, operations funding should
be provided to cover physician’s expenses in
administering the vaccines, which is not cur-
rently covered by the 317 Program.  TFAH
and IDSA recommend at least $800 million in
funding for the 317 Program in FY 2011.
 Congress should build on the innovations that
result from the one-time $300 million in sup-
plemental funding from ARRA and provide a
distinct funding stream to be used by states in
enhancing their outreach efforts to adults in
the FY 2011 budget.
 Congress should be commended for including
a mandate for full coverage of all ACIP-recom-
mended immunizations for all insured Ameri-
cans as part of the pending health reform
legislation.  Regardless of the outcome of that
debate, steps must be taken to provide funds
to cover immunizations for those who will re-
main uninsured and to cover costs of immu-
nizations during the time of transition where
benefits are being extended post-reform.  A
Vaccines for Uninsured Adults (VFUA) Pro-
gram that would help ensure that adult vac-
cines become a routine entitlement, similar to
the VFC Program, should be created.  Impor-
tant legislation was introduced in the 110th
Congress to establish such a program (see Vac-
cines for the Uninsured proposal text box).
 Congress and HHS should act to ensure that
Medicare beneficiaries receive coverage for all
preventive vaccines under Medicare Part B in-
stead of covering most vaccines under Part D.
Part B procedures are straightforward and al-
ready cover influenza, pneumococcal and hep-
atitis B vaccines.  Health reform legislation
passed by the U.S. House of Representatives in
2009 includes a provision that would transfer
Medicare-covered vaccines from Part D to Part
B. Legislation was also introduced in the 110th
Congress to transfer all Medicare-covered vac-
cines from Part D to Part B (see Vaccines for the
Uninsured proposal text box).
 The Centers for Medicare and Medicaid Serv-
ices (CMS) should require institutions, as a
condition of participating in the Medicare
program, to offer annual influenza vaccina-
tion to all health care personnel, report an-
nual vaccination rates, and undertake
vigorous promotional campaigns to increase
vaccine acceptance.  Mandatory policies for
institutions receiving Medicare payments
should be considered.
 Congress should increase funding to permit
CDC to increase its capacity to measure adult
immunization coverage rates and support en-
hanced development, interoperable functional-
ity, and use of state and regional immunization
registries and/or take advantage of advances in
electronic medical health records. 
 All health care workers should play an in-
creased role in reducing transmission of dis-
ease and set an example by complying with the
immunization recommendations from ACIP
to protect themselves, their staffs, and their pa-
tients.  This includes receiving an annual in-
fluenza vaccination to protect themselves and
their patients.  IDSA supports “universal im-
munization of health care workers against sea-
sonal and 2009 H1N1 influenza by health care
institutions (inpatient and outpatient)
through mandatory vaccination programs as
those programs are likely to be the most ef-
fective means to protect patients against the
transmission of seasonal and H1N1 influenza
by [health care workers].”64
Mirroring the patient immunization offer man-
dates at nursing homes, more hospitals and
health facilities should develop policies to offer
vaccinations to eligible adult inpatients and out-
patients.  There should be adequate payment
to hospitals for vaccine acquisition, storage, and
administration. The Joint Commission should
establish criteria for assessing influenza, per-
tussis, and hepatitis B immunization rates in
health care workers as a measure of institutional
compliance and performance.
16
 Congress should provide the National Insti-
tutes of Health (NIH), CDC and FDA with in-
creased support for vaccine-safety surveillance
and research. 
HHS agencies (CDC, the Agency for Health-
care Research and Quality, CMS, HRSA), the
Department of Defense, the Department of
Veterans Affairs, and the Federal Bureau of
Prisons should conduct assessments of barriers
to adult immunization within their own pro-
grams, collect data regularly about immuniza-
tion rates and practices within their settings,
conduct research to evaluate and eliminate
barriers to immunization, and receive the re-
sources to accomplish these goals.
Medicare and Medicaid vaccine administra-
tion fees must be increased to cover
providers’ actual cost of administration.
 Private payers should provide coverage for all
ACIP-recommended adult vaccines and con-
sider administration fees provided by Medicare
Part B to be the minimal standard.  If a federal
mandate does not occur as part of health re-
form, states should require full coverage of
ACIP-recommended vaccines.
 The National Committee on Quality Assur-
ance should work toward including every
adult vaccine recommended by ACIP in the
Health Plan Employer Data and Information
Set (HEDIS), a set of measures that reflect
quality of care in managed care and other
health care settings. 
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3. STRENGTHEN PRIVATE INSURANCE COVERAGE OF ADULT
VACCINES
 Research supported by BARDA, NIH, CDC,
FDA, and other federal agencies must be
funded sufficiently to support the develop-
ment of new adult vaccines, as well as im-
provements in existing vaccines. Effectiveness,
safety and cost-benefit should be considered. 
 Congress should appropriate $1.7 billion for
FY 2011 in the Public Health and Social Serv-
ices Emergency Fund (PHSSEF) for BARDA’s
advanced research and development mission.
 Health services research should be funded to
study public and provider acceptance of vac-
cines, safety concerns among the public, and
racial, ethnic, and economic disparities in im-
munization rates, and to implement and eval-
uate interventions designed to eliminate un-
necessary concerns and disparities.
 Congress should provide incentives that sup-
port vaccine development and production by
industry within the United States to help assure
adequate supplies of vaccine, especially in times
of crisis.  Steps should be taken to stabilize the
vaccine market by assuring that vaccines will be
purchased once produced.  The announced in-
tent of governments to guarantee purchases of
fixed amounts of vaccines has helped to stabi-
lize production in some cases and encourage
continued research and development.
4. SUPPORT ADDITIONAL RESEARCH INTO ADULT VACCINES
VACCINES FOR THE UNINSURED PROPOSAL
In the 110th Congress, Representative Henry A. Waxman, (D-CA), chair of the House Energy and
Commerce Committee, sponsored legislation to strengthen adult and adolescent immunization.  One
bill, H.R. 4933, would have established a Vaccines for Uninsured Adults program, modeled after the
successful Vaccines For Children program. The measure proposed creating an entitlement program
for all low income adults to receive free vaccines, and for physicians to receive a fee for providing the
immunizations. The bill also proposed authorizing programs to educate the public about the impor-
tance of adult immunization and permit grants to states to strengthen state adult immunization ef-
forts. In addition, the legislation would require CMS, through increased research, to find more
effective ways to encourage adults and, specifically, health care workers to get immunized.  The
measure would authorize $800 million annually for the first five years to implement these changes.
Another bill, H.R. 4992 in the 110th Congress, focused on helping older Americans by moving vaccine
coverage from Medicare Part D to Medicare Part B, thereby removing obstacles to vaccine delivery
and providing administration fees to doctors for vaccinating patients.  
5. INCREASE RESOURCES FOR STATE AND LOCAL HEALTH
DEPARTMENTS’ VACCINATION CAMPAIGNS 
 Sufficient resources must be provided to state
and local health departments to conduct suc-
cessful vaccination campaigns.  Such campaigns
should reach out to adults to inform them
about the availability, benefits, and safety of vac-
cines, as well as maintain vaccination clinics to
administer vaccines to the general public, but
particularly the uninsured and underinsured.
Sufficient funding is an ongoing challenge.  In
2009, the National Association of County and
City Health Officials surveyed a sample of local
health departments (LHDs) nationwide to
measure the impact of current economic con-
ditions on LHDs’ budgets, workforce, and pro-
grams. The report found that LHDs had begun
to eliminate or reduce vital programs and staff.
In the first half of 2009, approximately 8,000
staff positions in LHDs were lost due to layoffs
or attrition. An additional 12,000 LHD em-
ployees were subjected to reduced hours or
mandatory furloughs.  The response efforts to
the novel Influenza H1N1 outbreak would not
have been possible without one-time and lim-
ited federal funding and the shifting of staff re-
sources from other programs. 
Ongoing support must be provided to ensure
that state and LHDs have continuous capacity
to support vaccination and public health pro-
grams that help support vaccine efforts.  Often
vaccination campaigns are funded as “just-in-
time” or one-time campaigns instead of an on-
going continued service.
APPENDIX A: COMMUNITIES TAKING ACTION:  
SUCCESS STORIES AND INNOVATIONS 
Vax and Vote
In an effort to increase the rates of those re-
ceiving flu shots, the Robert Wood Johnson
Foundation (RWJF), together with Sickness Pre-
vention Achieved through Regional Collabora-
tion (SPARC), created the Vote and Vax
initiative to provide flu vaccination clinics at or
near polling centers across the country.  
The program first started in 2004, and has
helped to provide thousands of vaccinations to
at-risk Americans.  In recent years the efforts
have been expanded, and in November 2008
Vote and Vax delivered 21,434 flu shots at 331
locations in 42 states and the District of Colum-
bia.65 Almost half of those vaccinated reported
that they had either not received a flu shot the
previous year or would not have been vaccinated
but for the Vote and Vax program.
Colorado: A Decade of Targeting Adults
Colorado places a special emphasis on adult im-
munization. For the past 10 years, the goal of the
state’s Influenza and Adult Immunization Coali-
tion has been to decrease vaccine-preventable
diseases through collaborative efforts in educa-
tion and immunization.
Located within the state department of public
health, the program uses, among other things,
community outreach, media, and provider edu-
cation to spread the message. The state does not
run immunization clinics, but provides vaccines
to community clinics, such as church-based or
mobile clinics, that deliver immunizations to un-
derserved populations, such as the homeless.
Coalition officials meet monthly with commu-
nity clinics, pharmacies (which under state law
can administer shots), vaccine manufacturers,
and local public health agencies, among others,
to coordinate efforts. They also work with a local
television station, which sponsors health fairs, to
distribute posters and brochures that encourage
immunization.  
“Originally we were mostly concerned with flu and
pneumococcal vaccination,’’ says Margaret Huff-
man, ND, RN, the provider services unit manager
for Colorado’s immunization program. “Since the
introduction of the zoster vaccine, HPV and the
Tdap recommendations, we highlight all the im-
munizations that adults should be considering.”66
The program uses money from Section 317 to
fund its activities. Its greatest success has been
with the state’s elderly. “We really do well with
our seniors,” Huffman says. “We are one of the
top states with flu and pneumococcal vaccines.
We don’t do as well with our younger adults, but
we are working on it.”67 
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Howard County, Maryland: Drive-through Flu Shots
Howard County, Maryland has a convenient and
relatively quick way to deliver seasonal flu shots:
a drive-through clinic. People don’t leave their
cars -- they just roll up their sleeves, roll down
their windows, and stick out their arms.
“It is just as easy as getting fast food, and a lot
better for you,” says Peter Beilenson, MD, the
county’s health officer.68
During the three years the drive-through has
been operating, the biggest challenges have been
logistics and traffic control. Beilenson says the
process has gotten better and faster each year.
This past fall, the county delivered shots to 4,000
people in five hours from a large parking lot that
surrounds a local warehouse. The shots are free,
paid for by the county health department.
“We set the clinic up in a huge circular driveway,
with police directing traffic,’’ says Beilenson, the
former Baltimore City Health Commissioner.
“People fill out consent forms while waiting in
line, and then move on. We have about 10 or 12
lanes. People literally just drive by and hold out
their arms. It’s extremely simple, and we can get
a massive number of people through.”69
This is not the only such drive-through opera-
tion in the country.  The Department of Veter-
ans Affairs, for example, also sponsors local
drive-through immunization clinics in various
locations around the country.
Public health experts recommend generally that
a post-immunization waiting period be incorpo-
rated into drive-through clinic plans, to provide
protection against the possibility some people
may feel dizzy after receiving an immunization.  
Immunize LA Families
Immunize LA Families, part of the South Los
Angeles Health Projects, successfully uses the
federally funded Women, Infants and Children
(WIC) nutrition program as a place to reach
families in order to encourage pediatric immu-
nization. It now plans to do the same with in-
fluenza vaccination among adult pregnant
women who use WIC services.  
“WIC is one place where you can reach women
and children, and we have one of the biggest WIC
programs in the country,’’ says Steve Baranov,
Vice President for Community Health at the Los
Angeles Biomedical Research Institute, Harbor-
UCLA Medical Center, and Executive Director of
South Los Angeles Health Projects. “We enroll
20,000 pregnant women every year. Now, let’s see
if we can get them to go get immunizations.”70
Immunize LA Families also hopes to initiate adult
immunization outreach activities in churches,
senior citizen centers and other sites, with sup-
port from the Racial and Ethnic Approaches to
Community Health (REACH) program, created
by CDC to support community coalitions that
work to eliminate racial and ethnic health dis-
parities.  At present, Immunize LA Families re-
ceives less than $500,000 a year from CDC’s
REACH program.  “If we could double our
budget, we could do much more,” Baranov says.71 
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APPENDIX B
Joint Statement of Medical Societies Regarding Adult Vaccination by Physicians 
Signed: 
Summary: 
In an effort to emphasize the importance of
adult vaccination against an increasing number
of vaccine-preventable diseases, primary care
and many subspecialty physicians should take an
active role in the discussion and review of their
adult patients’ vaccination status and in the ad-
ministration of recommended vaccines. In-
creased consumer demand for quality care, and
guidelines and/or recommendations from the
CDC and professional societies provide addi-
tional impetus for a renewed and stronger em-
phasis on provision of vaccines. 
The Potential Role of Subspecialists: 
Primary care is the most convenient and ap-
propriate setting for delivery of vaccines to
most adult patients, since it serves as their
“medical home.” However, many patients with
chronic disease also have a “medical home”
with a subspecialist. For example, infectious
disease physicians often provide primary and
preventive care services for patients with HIV
infection. Other subspecialists also may serve
as the preferred source of care for their pa-
tients with chronic disease, providing an op-
portunity to serve as a source of vaccination
administration or referral. 
It is proposed that: 
(1) Primary and subspecialty physicians should
conduct immunization review at appropriate
adult medical visits to educate patients about the
benefits of vaccination and to assess whether the
patient’s vaccination status is current, referring
to the Advisory Committee on Immunization
Practices Adult Immunization Schedule. 
(2) When appropriate, physicians should provide
or refer patients for recommended immunizations. 
(3) Physicians who administer vaccines should en-
sure appropriate documentation in the medical
record. In addition, documentation of vaccination
in other settings, patient refusal, and any con-
traindications is advisable. The use of immunization
registries and electronic data systems facilitates ac-
cess to accurate and complete immunization data. 
(4) Physicians who refer patients for vaccination
also should review and document the vaccina-
tion status of their patients whenever possible. 
(5) Consistent with the CDC Advisory Commit-
tee on Immunization Practices and multiple
subspecialty organizations, physicians and their
staff should be immunized consistent with CDC
recommendations, with particular attention to
annual influenza immunization. 
American College of Physicians 
Infectious Diseases Society of America 
Society of Hospital Medicine 
American Association of Clinical Endocrinologists 
American Association for the Study of Liver Diseases 
Society of General Internal Medicine 
American Society of Hematology 
Society for Adolescent Medicine 
American College of Chest Physicians 
American College of Allergy, Asthma and
Immunology 
American Gastroenterological Association 
The Endocrine Society 
The American Academy of Allergy, Asthma
and Immunology 
American College of Gastroenterology 
American Society of Clinical Oncology 
American Society of Nephrology 
American College of Cardiology 
American Thoracic Society 
The Society for Healthcare Epidemiology 
of America
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APPENDIX C: TYPES OF VACCINES AND 
VACCINE PRODUCTION 
Current Vaccines72
There are many different kinds of vaccines.
Live, attenuated vaccines contain a version of
the living microbe that has been weakened in
the lab so it does not cause disease. This kind of
vaccine is the closest thing to a natural infection;
thus, it can elicit strong cellular and antibody re-
sponses and produce lifelong immunity with
only one or two doses. Not everyone can safely
receive this kind of vaccine.  People with weak-
ened immune systems, for example, should not
receive live vaccines. These vaccines need to be
refrigerated or frozen to keep their strength.
Vaccines against measles, mumps, chickenpox
and shingles are live attenuated vaccines.  
Inactivated vaccines are those made by killing the
disease-causing organism with chemicals, heat, or
radiation. These are more stable than live vaccines
and may be safer. However, most of these vaccines
stimulate a weaker immune system response than
do live vaccines, requiring several additional
doses, or booster shots, to maintain immunity. 
Subunit vaccines include only those parts (anti-
gens) that best stimulate the immune system,
rather than the entire microbe. The chances of ad-
verse effects from these vaccines are generally
lower than with other types. Once scientists iden-
tify which antigens are the most important in in-
ducing infection, they may be able to either grow
the microbe in the laboratory and use chemicals to
break it apart, or manufacture the antigen mole-
cules from the microbe using recombinant DNA
technology. Vaccines produced this way are called
recombinant subunit vaccines. The vaccine for
hepatitis B is a recombinant subunit vaccine.  Poly-
saccharide vaccines are a type of subunit vaccine.
They are made from pieces of the polysaccharide
capsule that surrounds certain bacteria. Polysac-
charide vaccines are generally less effective than
live attenuated vaccines and inactivated vaccines
that are based on protein. They also are not very
effective in infants and children under two years
of age. The pneumococcal vaccine for adults is a
polysaccharide vaccine. Conjugate vaccines are an-
other type of subunit vaccine.  They are made by
joining the polysaccharide capsule that surrounds
the bacterium to a protein carrier. This makes the
vaccine effective in infants and young children. Ex-
amples include Haemophilus influenzae type b (Hib)
and pneumococcal vaccines for children. 
Toxoid vaccines are used to prevent illness caused
by poisons developed by some bacteria.  Scientists
inactivate these toxins by treating them with for-
malin, a solution of formaldehyde and sterilized
water. Such “detoxified” toxins, called toxoids, are
safe for use in vaccines. When the immune system
receives a vaccine containing a toxoid, it develops
antibodies to fight off the natural toxin. The im-
mune system produces antibodies that lock onto
and block the toxin. Vaccines against diphtheria
and tetanus are examples of toxoid vaccines.
Chemicals commonly used in the production of
vaccines include a suspending fluid (sterile water,
saline, or fluids containing protein); preservatives
and stabilizers (for example, albumin, phenols,
and glycine); and adjuvants, or enhancers, which
help improve the vaccine’s effectiveness. Vaccines
also may contain very small amounts of the cul-
ture material used to grow the virus or bacteria
used in the vaccine, such as chicken egg protein.   
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Vaccines of the Future73
DNA vaccines are still in experimental stages.
DNA vaccines use the genes that code for those
all-important antigens. Researchers have found
that when the genes for a microbe’s antigens are
introduced into the body, some cells will take up
that DNA. The DNA then instructs those cells to
make the antigen molecules. The cells secrete
the antigens and display them on their surfaces.
In other words, the body’s own cells become vac-
cine-making factories, creating the antigens nec-
essary to stimulate the immune system. 
Recombinant vector vaccines are experimental
vaccines similar to DNA vaccines, but they use an
attenuated virus or bacterium to introduce mi-
crobial DNA to cells of the body. “Vector” refers
to the virus or bacterium used as the carrier.
APPENDIX D:  METHODOLOGY FOR PNEUMONIA
AND SEASONAL INFLUENZA VACCINATIONS
Data for this analysis was obtained from the Be-
havioral Risk Factor Surveillance System
(BRFSS) dataset (publicly available on the web
at cdc.gov/brfss).74 To conduct the analyses,
TFAH contracted with Edward N. Okeke, PhD,
MBBS, MPH at the Department of Health Man-
agement and Policy at the University of Michi-
gan School of Public Health.  
To account for the complex nature of the sur-
vey design and obtain estimates accurately rep-
resentative at the state level, we used sample
weights provided by the CDC in the dataset. The
main purpose of weighting is to reduce bias in
population estimates by up-weighting popula-
tion sub-groups that are under represented and
down-weighting those that are over represented
in the sample. Also estimation of variance, which
indicates precision and is used in calculating
confidence intervals, needs to take into account
the fact that the elements in the sample will gen-
erally not be statistically independent as a result
of the multistage sampling design.  
We specified the sampling plan to STATA75 using
the svyset command and the following set of
weights: sample weight variable (FINALWT), first-
stage stratification variable (STSTR), and primary
sampling unit variable (PSU). Omission of the
stratification variable in STATA implies no strati-
fication of PSUs prior to first-stage sampling.
Omission of the primary sampling unit variable
implies one-stage sampling of elements and no
clustering of sampled elements. Omission of the
sample weight implies equally weighted sample el-
ements. Mean proportions for each variable were
estimated using the svy: proportion command. 
For pneumococcal vaccination, the individual is
asked whether he/she has ever received a pneu-
monia shot. In all cases we exclude observations
with missing data as well as observations where
the individual either refused to answer, or
replied, “Don’t know.” This never amounted to
more than 5 percent of the observations.
For the seasonal influenza analysis, the variable
of interest was the FLUSHOT variable.76 Re-
searchers weighted data from 2008 using sample
weights provided by the CDC in the dataset and
dropped observations where either the survey
participant answered, “don’t know” or refused to
answer. These accounted for less than 0.5 percent
of all observations. Researchers then calculated
influenza vaccination rates for three different
population samples – individuals aged 18-49, in-
dividuals aged 50-64, and individuals 65 and older
– for each state. The research team reported 2008
influenza vaccination rates for each sub-sample,
along with standard errors and 95 percent confi-
dence intervals. Respective sample sizes for each
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